In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we track German physicians’ awareness of Truxima and its uptake since its launch to understand how its entry will impact the non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and the increasingly competitive immune biologics market. Along with physicians’ awareness of, familiarity with, and perceptions of biosimilars in general and of Truxima specifically, we explore the drivers of and barriers to the uptake of biosimilars/Truxima. We examine promotional efforts, as well as prescriber and nonprescriber profiles, and compare Truxima with other available biosimilars, to better understand the dynamics of the German biosimilars market.

Questions Answered

  • Are German physicians aware of Truxima and its clinical development?
  • What are the drivers to prescribing Truxima? What is the current level of Truxima use, and how is it changing over time?
  • Has experience with Truxima changed physicians’ opinions of biosimilars?
  • Have physicians experienced pressure to prescribe Truxima to patients?
  • What promotional messages are sales representatives using to sell Truxima and MabThera?

Table of contents

  • Oncology & Immunology: Truxima Launch Tracking (Germany) Wave 1
    • Key Findings
      • Biosimilar Prescriber and Nonprescriber Profiles
        • Differences Between Truxima Prescribers and Nonprescribers
    • Benchmarking Truxima's Launch Success vs. Other Biosimilar Launches
    • Market Access Analysis
      • Reimbursement of Biosimilars in Germany
      • Biosimilar Pricing
      • Drivers of Biosimilar Uptake
      • German Payers' Opinion of the Market Impact of Biosimilar Rituximab
    • Awareness and Perceptions of Truxima
      • Awareness of and Familiarity with Truxima
        • Unaided Awareness of Drugs for NHL/CLL and RA
        • Familiarity with Biosimilars and Truxima
      • Perceptions of Truxima
        • Physician Perceptions of Truxima's Clinical Development
        • Physician Perceptions of Truxima's Approved Indications
    • Trial and Use
      • Current Use of Truxima
        • Experience with NHL/CLL and RA Drugs
        • Current Use of Truxima
        • Truxima Patient Types
        • Satisfaction with Truxima
        • Truxima's Current Patient Share
      • Drivers of and Barriers to Truxima Use
        • Reasons to Prescribe Truxima
        • Reasons for Not Prescribing Truxima
        • Truxima's Net Cost
        • Prescriber Perception of Truxima's Similarity to MabThera
        • Anticipated Time to Start Prescribing Truxima
    • External Factors Affecting Use
      • Sources of Pressure or Recommendations to Use Truxima
        • Sources of Pressure or Recommendations to Use Truxima
        • Reference Pricing Expectations
      • Patients' Acceptance of Truxima
    • Promotional Activity
      • Promotional Activity for Truxima
    • Future Use of Biosimilars
      • Willingness to Prescribe Novel Biosimilars
        • Likelihood to Prescribe Novel Biosimilars
        • Willingness to Prescribe Novel Rituximab Biosimilars
      • Patient-Share Expectations for Truxima
        • Future Use of Rituximab Biosimilars
    • Appendix
      • Background on the German Rituximab Market
        • Background on Truxima's Development and Marketing
        • Current and Future Biosimilar Landscape
      • Market News
      • Methodology and Objectives
        • Objectives
        • Physician Research Methodology
        • Payer Research Methodology
      • Respondent Demographics
      • Abbreviations

Author(s): Amy Duval, M Res

Amy Duval , is a director in the oncology and biosimilars team at Decision Resources Group. Ms. Duval manages a team of analysts responsible for market research across oncology indications, and also provides client support across Decision Resources Group oncology products. Previously, Ms. Duval was a principal analyst in the oncology group, where she developed in-depth expertise in breast and ovarian cancer. Ms. Duval has worked on multiple oncology indications, including malignant melanoma, renal cell carcinoma, and lung cancer, and has worked on topics in both the major and emerging pharmaceutical markets. Ms. Duval earned her in natural sciences and in molecular and cellular biology from the University of Birmingham, where she conducted research into the epigenetics of leukemia.

Related Reports

Biomarkers in Oncology | Access & Reimbursement | Detailed, Expanded Analysis: Multi-indication (US)

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant me...

View Details

Biosimilars | Current Treatment | Oncology

In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb

View Details

Biosimilars | Access & Reimbursement | Oncology

This report is available to find out more click the link and fill out the form to get more details.

View Details

Biosimilars | Emerging Biosimilars | Oncology: Trastuzumab Biosimilars Launch Tracking (Germany) Wave 3

Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, three additional trastuzumab biosimila...

View Details